63 related articles for article (PubMed ID: 2903752)
1. [Behavior of circulating somatostatin in cirrhotic subjects: correlation with hepatic function].
Tanganelli I; Signorini AM; Gragnoli G
Boll Soc Ital Biol Sper; 1988 Mar; 64(3):251-6. PubMed ID: 2903752
[No Abstract] [Full Text] [Related]
2. Hyperglucagonemia in hepatic cirrhosis: its relation to hepatocellular dysfunction and normalization on recovery.
Kabadi UM; Eisenstein AB; Tucci J; Pellicone J
Am J Gastroenterol; 1984 Feb; 79(2):143-9. PubMed ID: 6364796
[TBL] [Abstract][Full Text] [Related]
3. Circulating somatostatin concentrations in healthy and cirrhotic subjects.
Verrillo A; de Teresa A; Martino C; Pinto M; Golia R
Metabolism; 1986 Feb; 35(2):130-5. PubMed ID: 2868381
[TBL] [Abstract][Full Text] [Related]
4. Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics.
Tietge UJ; Böker KH; Manns MP; Bahr MJ
Am J Physiol Endocrinol Metab; 2004 Jul; 287(1):E82-9. PubMed ID: 15010338
[TBL] [Abstract][Full Text] [Related]
5. Effects of glucose on hepatic conversion of aminonitrogen to urea in patients with cirrhosis: relationship to glucagon.
Hamberg O; Vilstrup H
Hepatology; 1994 Jan; 19(1):45-54. PubMed ID: 7903954
[TBL] [Abstract][Full Text] [Related]
6. [Somatostatin plasma level in patients with liver cirrhosis].
Tulassay Z; Tulassay T; Szabó A; Jaszovszky I; Gohér A
Orv Hetil; 1995 May; 136(22):1163-5. PubMed ID: 7761079
[TBL] [Abstract][Full Text] [Related]
7. [Behavior of plasma insulin, C-peptide and glucagon in normal subjects and in patients with liver cirrhosis].
Gragnoli G; Tanganelli I; Signorini AM
Boll Soc Ital Biol Sper; 1980 Jan; 56(1):69-75. PubMed ID: 7002168
[TBL] [Abstract][Full Text] [Related]
8. [Changes in plasma glucagon, insulin, C-peptide and amino acids during the intravenous induced hyperammonemia test in the cirrhotic].
Doffoël M; Zarski JP; Schlienger JL; Raul F; Marescarux J; Imler M; Bockel R
Gastroenterol Clin Biol; 1981 Dec; 5(12):1087-94. PubMed ID: 7033034
[No Abstract] [Full Text] [Related]
9. Effect of somatostatin on splanchnic hemodynamics in patients with cirrhosis of the liver and in normal subjects.
Sonnenberg GE; Keller U; Perruchoud A; Burckhardt D; Gyr K
Gastroenterology; 1981 Mar; 80(3):526-32. PubMed ID: 6108898
[TBL] [Abstract][Full Text] [Related]
10. [The cyclic AMP, insulin and glucose responses to glucagon stimulation in patients with liver cirrhosis according to the stage of development ].
Esteva Díaz F; Ducóns García J; Ceña Lázaro G; Márquez Galván M; Juste Rullo G; Barrao Comps F
Rev Clin Esp; 1986 Nov; 179(7):347-51. PubMed ID: 3025944
[No Abstract] [Full Text] [Related]
11. Plasma levels of PBEF/Nampt/visfatin are decreased in patients with liver cirrhosis.
de Boer JF; Bahr MJ; Böker KH; Manns MP; Tietge UJ
Am J Physiol Gastrointest Liver Physiol; 2009 Feb; 296(2):G196-201. PubMed ID: 19074645
[TBL] [Abstract][Full Text] [Related]
12. Elevation of plasma glucagon-like immunoreactivity (GLI) in patients with liver cirrhosis.
Watanabe A; Hashimoto M; Higashi T; Kobayashi M; Nakatsukasa H; Yamauchi Y; Watanabe M; Fujiwara M; Nagashima H
J Med; 1986; 17(2):95-108. PubMed ID: 3473162
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic glucoregulatory hormones in cirrhosis of the liver: portal vein concentrations during intravenous glucose tolerance test and in response to a meal.
Holst JJ; Burcharth F; Kühl C
Diabete Metab; 1980 Jun; 6(2):117-27. PubMed ID: 6997101
[TBL] [Abstract][Full Text] [Related]
14. [Behavior of immunoreactive insulin, "big insulin" and the somatotropic hormone in cirrhotic patients with diabetes mellitus].
Gragnoli G; Genazzani AR; Tanganelli I; Palazzuoli V; Felber JP
Folia Endocrinol; 1974 Apr; 27(2):196-211. PubMed ID: 4406492
[No Abstract] [Full Text] [Related]
15. Elevated plasma somatostatin in cirrhosis of the liver.
Munkgaard S; Kelbaek H; Tronier B
N Engl J Med; 1981 Jun; 304(23):1429-30. PubMed ID: 6112708
[No Abstract] [Full Text] [Related]
16. [Effect of somatostatin on splanchnic hemodynamics in liver cirrhosis].
Merkel C; Gatta A; Zuin R; Finucci GF; Arnaboldi L; Ruol A
Minerva Med; 1984 Nov; 75(44):2673-8. PubMed ID: 6151151
[TBL] [Abstract][Full Text] [Related]
17. Fasting plasma somatostatin in alcoholic liver disease.
Kelbaek H; Tronier B; Bahnsen M; Munkgaard S; Pedersen H
Scand J Clin Lab Invest; 1983 Nov; 43(7):597-601. PubMed ID: 6140748
[TBL] [Abstract][Full Text] [Related]
18. Prandial regulation of ghrelin secretion in humans: does glucagon contribute to the preprandial increase in circulating ghrelin?
Soule S; Pemberton C; Hunt P; Cole D; Raudsepp S; Inder W
Clin Endocrinol (Oxf); 2005 Oct; 63(4):412-7. PubMed ID: 16181233
[TBL] [Abstract][Full Text] [Related]
19. Circulating transforming growth factor beta(1) as an indicator of hepatic function impairment in liver cirrhosis.
Flisiak R; Pytel-Krolczuk B; Prokopowicz D
Cytokine; 2000 Jun; 12(6):677-81. PubMed ID: 10843744
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin and glucose homeostasis in liver cirrhosis of the elderly.
Buzzelli G; Cotrozzi G; Relli P; Strazzulla G; Betti L; Brocchi A; Cappelli G; Coletta D; Simondi P; Matassi L
Ann Ital Med Int; 1987; 2(4):294-8. PubMed ID: 2908591
[No Abstract] [Full Text] [Related]
[Next] [New Search]
